WO2003032994A3 - 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren - Google Patents

5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren Download PDF

Info

Publication number
WO2003032994A3
WO2003032994A3 PCT/EP2002/011345 EP0211345W WO03032994A3 WO 2003032994 A3 WO2003032994 A3 WO 2003032994A3 EP 0211345 W EP0211345 W EP 0211345W WO 03032994 A3 WO03032994 A3 WO 03032994A3
Authority
WO
WIPO (PCT)
Prior art keywords
production
medicament
substituted pyrimidines
novel tri
tri
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/011345
Other languages
English (en)
French (fr)
Other versions
WO2003032994A2 (de
Inventor
Frank Himmelsbach
Klaus Fuchs
Hans Briem
Katja Fechteler
Markus Kostka
Cornelia Dorner-Ciossek
Klaus Bornemann
Klaus Klinder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Priority to EP02772368A priority Critical patent/EP1453516A2/de
Publication of WO2003032994A2 publication Critical patent/WO2003032994A2/de
Publication of WO2003032994A3 publication Critical patent/WO2003032994A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Die vorliegende Erfindung betrifft trisubstituierte Pyrimidine der Formel (I), worin Ra bis Re wie im Anspruch 1 definiert sind, welche zur Behandlung von Krankheiten, in denen β-Amyloid Modulatoren einen therapeutischen Nutzen entfalten, geeignet sind, deren Verwendung zur Herstellung eines Arznei-mittels mit den vorstehend erwähnten Eigenschaften, und Verfahren zu ihrer Herstellung.
PCT/EP2002/011345 2001-10-17 2002-10-10 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren Ceased WO2003032994A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP02772368A EP1453516A2 (de) 2001-10-17 2002-10-10 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33012801P 2001-10-17 2001-10-17
US60/330,128 2001-10-17

Publications (2)

Publication Number Publication Date
WO2003032994A2 WO2003032994A2 (de) 2003-04-24
WO2003032994A3 true WO2003032994A3 (de) 2003-06-12

Family

ID=23288430

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/011345 Ceased WO2003032994A2 (de) 2001-10-17 2002-10-10 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren

Country Status (3)

Country Link
US (2) US20030134838A1 (de)
EP (1) EP1453516A2 (de)
WO (1) WO2003032994A2 (de)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7456176B2 (en) 2004-04-08 2008-11-25 Targegen, Inc. Benzotriazine inhibitors of kinases
US7517886B2 (en) 2002-07-29 2009-04-14 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US7528143B2 (en) 2005-11-01 2009-05-05 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US7557210B2 (en) 2002-02-01 2009-07-07 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9108944B2 (en) 2010-02-16 2015-08-18 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
US9248190B2 (en) 2005-06-08 2016-02-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US9266912B2 (en) 2005-01-19 2016-02-23 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US9340524B2 (en) 2013-01-15 2016-05-17 Aragon Pharmaceuticals, Inc. Androgen receptor modulator and uses thereof

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002312933B2 (en) 2001-05-29 2007-12-06 Schering Ag CDK inhibiting pyrimidines, production thereof and their use as medicaments
CA2451128A1 (en) 2001-06-26 2003-01-09 Bristol-Myers Squibb Company N-heterocyclic inhibitors of tnf-alpha expression
DK1438053T3 (da) * 2001-10-17 2008-12-08 Boehringer Ingelheim Pharma Pyrimidinderivater, lægemiddel indeholdende disse forbindelser, deres anvendelse og fremgangsmåder til deres fremstilling
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
KR20050084027A (ko) * 2002-11-28 2005-08-26 쉐링 악티엔게젤샤프트 Ｃｈｋ-, ｐｄｋ- 및 ａｋｔ-억제성 피리미딘, 그의제조방법 및 약제로서의 그의 용도
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
EA013248B1 (ru) * 2002-12-20 2010-04-30 Пфайзер Продактс Инк. Производные пиримидина для лечения патологического роста клеток
WO2005003103A2 (en) * 2003-06-30 2005-01-13 Astrazeneca Ab 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases
CN102358738A (zh) 2003-07-30 2012-02-22 里格尔药品股份有限公司 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途
US7652051B2 (en) 2004-08-25 2010-01-26 Targegen, Inc. Heterocyclic compounds and methods of use
JP5095409B2 (ja) 2004-11-24 2012-12-12 ライジェル ファーマシューティカルズ， インコーポレイテッド スピロ２，４−ピリミジンジアミン化合物およびその使用
WO2006076644A2 (en) * 2005-01-14 2006-07-20 Chemocentryx, Inc. Heteroaryl sulfonamides and ccr2
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
US20060247250A1 (en) * 2005-03-16 2006-11-02 Targegen, Inc. Pyrimidine inhibitors of kinases
WO2006103038A1 (en) * 2005-03-30 2006-10-05 Boehringer Ingelheim International Gmbh Substituted 1,2-ethylendiamines, medicaments comprising said compound; their use and their method of manufacture
US20060270694A1 (en) * 2005-05-03 2006-11-30 Rigel Pharmaceuticals, Inc. JAK kinase inhibitors and their uses
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
CA2611720A1 (en) * 2005-06-08 2006-12-14 Targegen, Inc. Methods and compositions for the treatment of ocular disorders
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
CA2617294A1 (en) * 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii
CA2618474A1 (en) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Compounds for treating alzheimer's disease
JP2009504611A (ja) * 2005-08-11 2009-02-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルツハイマー病の治療用β−セクレターゼインヒビター
JP2009504614A (ja) * 2005-08-11 2009-02-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルツハイマー病の治療用化合物
US20090042867A1 (en) * 2005-08-11 2009-02-12 Klaus Fuchs Compounds for the treatment of alzheimer's disease
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
US8133900B2 (en) * 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US20070161645A1 (en) * 2005-11-02 2007-07-12 Targegen, Inc. Thiazole inhibitors targeting resistant kinase mutations
JP2009528295A (ja) 2006-02-24 2009-08-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｊａｋ経路の阻害のための組成物および方法
AU2016201061B2 (en) * 2006-03-27 2017-03-02 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
AU2013205325B2 (en) * 2006-03-27 2016-03-24 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
ES2689292T3 (es) 2006-03-27 2018-11-13 The Regents Of The University Of California Modulador del receptor de andrógenos para el tratamiento del cáncer de próstata y enfermedades asociadas con el receptor de andrógenos
AU2012241184B2 (en) * 2006-03-27 2016-01-07 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
NZ572374A (en) * 2006-03-29 2011-12-22 Univ California Diarylthiohydantoin compounds
KR20090023698A (ko) 2006-06-15 2009-03-05 베링거 인겔하임 인터내셔날 게엠베하 2-아닐리노-4-아미노알킬렌아미노피리미딘
EP2054392A2 (de) 2006-06-15 2009-05-06 Boehringer Ingelheim International GmbH 2-anilino-4-(heterocyclische)amino-pyrimidine als proteinkinase-c-alpha-hemmer
US8030487B2 (en) 2006-07-07 2011-10-04 Targegen, Inc. 2-amino—5-substituted pyrimidine inhibitors
ES2555803T3 (es) 2006-10-23 2016-01-08 Cephalon, Inc. Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met
CN101820881B (zh) 2007-07-12 2013-05-01 坎莫森特里克斯公司 作为ccr2调节剂用于治疗炎症的稠合杂芳基吡啶基和苯基苯磺酰胺
EP2220050A2 (de) 2007-10-26 2010-08-25 The Regents Of The University Of California Diarylhydantoinverbindungen als androgenrezeptormodulatoren
WO2009071535A1 (en) * 2007-12-03 2009-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
AU2009216851B2 (en) 2008-02-22 2013-11-07 F. Hoffmann-La Roche Ag Modulators for amyloid beta
US8685972B2 (en) * 2008-08-13 2014-04-01 Merck Sharp & Dohme Corp. Pyrimidine derivatives for treatment of alzheimer's disease
TW201016676A (en) * 2008-10-03 2010-05-01 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
NZ596078A (en) 2009-05-12 2013-06-28 Janssen Pharmaceuticals Inc 1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
CA2768543C (en) * 2009-07-28 2017-06-20 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2011032656A1 (de) * 2009-09-18 2011-03-24 Bayer Cropscience Ag 5-fluor-2-thio-substituierte pyrimidin-derivate
US8354420B2 (en) 2010-06-04 2013-01-15 Genentech, Inc. Aminopyrimidine derivatives as LRRK2 inhibitors
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
SI2638031T1 (en) 2010-11-10 2018-02-28 Genentech, Inc. Pyrazole aminopyrimidine derivatives as LRRK2 modulators
CN115737643A (zh) 2012-09-26 2023-03-07 阿拉贡药品公司 用于治疗非转移性去势抵抗性前列腺癌的抗雄激素
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
IL307931A (en) * 2016-04-15 2023-12-01 Epizyme Inc Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
EP4134080B1 (de) 2016-11-23 2024-11-13 ChemoCentryx, Inc. Ccr2-inhibitoren zur verwendung bei der behandlung von nierenerkrankungen
WO2018195450A1 (en) 2017-04-21 2018-10-25 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
US10758540B2 (en) 2017-10-11 2020-09-01 Chemocentryx, Inc. Treatment of focal segmental glomerulosclerosis with CCR2 antagonists
MX2020003845A (es) 2017-10-16 2020-11-06 Aragon Pharmaceuticals Inc Antiandrógenos para el tratamiento de cáncer de próstata no metastásico resistente a la castración.
EP3966206B1 (de) 2019-05-10 2023-08-09 Deciphera Pharmaceuticals, LLC Heteroarylaminopyrimidin-amid-autophagie-inhibitoren und verfahren zur verwendung davon
EP3966207B1 (de) 2019-05-10 2023-11-01 Deciphera Pharmaceuticals, LLC Phenylaminopyrimidin-amid-autophagie-hemmer und verfahren zu ihrer verwendung
JP7626722B2 (ja) 2019-06-17 2025-02-04 デシフェラ・ファーマシューティカルズ，エルエルシー アミノピリミジンアミドオートファジー阻害剤およびその使用方法
CN115141150B (zh) * 2022-07-25 2024-04-26 南通大学 2,4,5-三取代嘧啶羟胺酰衍生物及其制备方法与应用

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0379806A2 (de) * 1988-12-29 1990-08-01 Mitsui Petrochemical Industries, Ltd. Pyrimidine und deren pharmazeutisch brauchbare Salze und deren Verwendung als Arzneimittel
JPH03127790A (ja) * 1989-10-11 1991-05-30 Morishita Pharmaceut Co Ltd Ｎ―（１ｈ―テトラゾール―５―イル）―２―アニリノ―５―ピリミジンカルボキシアミド類及びその合成中間体
DE4029650A1 (de) * 1990-09-19 1992-03-26 Hoechst Ag 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide
WO2001019825A1 (en) * 1999-09-15 2001-03-22 Warner-Lambert Company Pteridinones as kinase inhibitors
WO2001027105A1 (en) * 1999-10-12 2001-04-19 Takeda Chemical Industries, Ltd. Pyrimidine-5-carboxamide compounds, process for producing the same and use thereof
WO2001055148A1 (en) * 2000-01-27 2001-08-02 Warner-Lambert Company Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
WO2001083460A1 (en) * 2000-04-28 2001-11-08 Tanabe Seiyaku Co., Ltd. Cyclic compounds
WO2002004429A1 (en) * 2000-07-11 2002-01-17 Astrazeneca Ab Pyrimidine derivatives
WO2002066036A1 (en) * 2001-02-20 2002-08-29 Bristol-Myers Squibb Company 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators
WO2002096888A1 (de) * 2001-05-29 2002-12-05 Schering Aktiengesellschaft Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9012592D0 (en) 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US5703129A (en) * 1996-09-30 1997-12-30 Bristol-Myers Squibb Company 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production
JP2002503662A (ja) 1998-02-17 2002-02-05 テュラリク インコーポレイテッド 抗ウイルス性ピリミジン誘導体
ES2361146T3 (es) 1998-03-27 2011-06-14 Janssen Pharmaceutica Nv Derivados de la piramidina inhibitatoria de vih.
AU751573C (en) 1998-03-27 2003-10-09 Janssen Pharmaceutica N.V. HIV inhibiting pyrimidine derivatives
US6632820B1 (en) 1998-08-29 2003-10-14 Astrazeneca Ab Pyrimidine compounds
DE69933680T2 (de) 1998-08-29 2007-08-23 Astrazeneca Ab Pyrimidine verbindungen
US6245884B1 (en) * 1998-10-16 2001-06-12 Vivian Y. H. Hook Secretases related to alzheimer's dementia
DE19851421A1 (de) 1998-11-07 2000-05-11 Boehringer Ingelheim Pharma Neue Pyrimidine, deren Herstellung und Verwendung
JP3635238B2 (ja) 1998-11-10 2005-04-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｉｖの複製を阻害するピリミジン類
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
ES2283315T3 (es) 1999-09-16 2007-11-01 Tanabe Seiyaku Co., Ltd. Compuestos ciclicos de 6 miembros que contienen nitrogeno aromatico.
WO2001053255A1 (en) * 2000-01-24 2001-07-26 Merck Sharp & Dohme Limited Gamma-secretase inhibitors
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US6753410B2 (en) * 2000-03-02 2004-06-22 Merck & Co., Inc. Investigational compounds
WO2001075435A2 (en) * 2000-04-03 2001-10-11 Bristol-Myers Squibb Company Fluorescence assay for gamma-secretase activity and inhibitors
GB0016681D0 (en) * 2000-07-06 2000-08-23 Merck Sharp & Dohme Therapeutic compounds
MXPA03008437A (es) * 2001-03-22 2004-01-29 Bristol Myers Squibb Co Reduccion estereoselectiva de acetofenona substituida.
CN1304390C (zh) * 2001-08-03 2007-03-14 先灵公司 新颖的γ—分泌酶抑制剂
GB0223038D0 (en) * 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0379806A2 (de) * 1988-12-29 1990-08-01 Mitsui Petrochemical Industries, Ltd. Pyrimidine und deren pharmazeutisch brauchbare Salze und deren Verwendung als Arzneimittel
JPH03127790A (ja) * 1989-10-11 1991-05-30 Morishita Pharmaceut Co Ltd Ｎ―（１ｈ―テトラゾール―５―イル）―２―アニリノ―５―ピリミジンカルボキシアミド類及びその合成中間体
DE4029650A1 (de) * 1990-09-19 1992-03-26 Hoechst Ag 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide
WO2001019825A1 (en) * 1999-09-15 2001-03-22 Warner-Lambert Company Pteridinones as kinase inhibitors
WO2001027105A1 (en) * 1999-10-12 2001-04-19 Takeda Chemical Industries, Ltd. Pyrimidine-5-carboxamide compounds, process for producing the same and use thereof
EP1223170A1 (de) * 1999-10-12 2002-07-17 Takeda Chemical Industries, Ltd. Pyrimidin-5-carboximidverbindungen, verfahren zur herstellung derselben und deren verwendung
WO2001055148A1 (en) * 2000-01-27 2001-08-02 Warner-Lambert Company Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
WO2001083460A1 (en) * 2000-04-28 2001-11-08 Tanabe Seiyaku Co., Ltd. Cyclic compounds
EP1277741A1 (de) * 2000-04-28 2003-01-22 Tanabe Seiyaku Co., Ltd. Zyklische verbindungen
WO2002004429A1 (en) * 2000-07-11 2002-01-17 Astrazeneca Ab Pyrimidine derivatives
WO2002066036A1 (en) * 2001-02-20 2002-08-29 Bristol-Myers Squibb Company 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators
WO2002096888A1 (de) * 2001-05-29 2002-12-05 Schering Aktiengesellschaft Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BOSCHELLI D H ET AL: "SYNTHESIS AND TYROSINE KINASE INHIBITORY ACTIVITY OF A SERIES OF 2-AMINO-8-H-PYRIDOÄ2,3-DÜPYRIMIDINES: IDENTIFICATION OF POTENT, SELECTIVE PLATELET-DERIVED GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 41, no. 22, 1998, pages 4365 - 4377, XP002191993, ISSN: 0022-2623 *
PATENT ABSTRACTS OF JAPAN vol. 015, no. 332 (C - 0861) 23 August 1991 (1991-08-23) *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7557210B2 (en) 2002-02-01 2009-07-07 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US8835430B2 (en) 2002-02-01 2014-09-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9018204B1 (en) 2002-02-01 2015-04-28 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9913842B2 (en) 2002-02-01 2018-03-13 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9346765B2 (en) 2002-02-01 2016-05-24 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9416112B2 (en) 2002-02-01 2016-08-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7517886B2 (en) 2002-07-29 2009-04-14 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US7456176B2 (en) 2004-04-08 2008-11-25 Targegen, Inc. Benzotriazine inhibitors of kinases
US9532998B2 (en) 2005-01-19 2017-01-03 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US9266912B2 (en) 2005-01-19 2016-02-23 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US9248190B2 (en) 2005-06-08 2016-02-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US7528143B2 (en) 2005-11-01 2009-05-05 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US9108944B2 (en) 2010-02-16 2015-08-18 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
US9481664B2 (en) 2010-02-16 2016-11-01 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
US9340524B2 (en) 2013-01-15 2016-05-17 Aragon Pharmaceuticals, Inc. Androgen receptor modulator and uses thereof

Also Published As

Publication number Publication date
US20050090486A1 (en) 2005-04-28
EP1453516A2 (de) 2004-09-08
WO2003032994A2 (de) 2003-04-24
US20030134838A1 (en) 2003-07-17
US7166599B2 (en) 2007-01-23

Similar Documents

Publication Publication Date Title
EP1251126A3 (de) Fluor-substituierte benzensulfonyl-derivate zur behandlung von entzündungen
WO2004006858A3 (en) Compounds, compositions, and methods employing same
CA2272584A1 (en) Novel substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
WO2004045618A3 (de) Neue arzneimittel zur behandlung von chronisch obstruktiver lungenerkrankung
SI2527315T1 (sl) Spojine, sestavki in metode za zdravljenje amiloidnih bolezni in sinukleinopatij, kot so Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsonova bolezen
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
WO2003044021A3 (en) Substituted indolizine-like compounds and methods of use
UA84025C2 (en) Normal;heading 1;heading 2;2-(QUINOXALIN-5-YLSULFONYLAMINO)-BENZAMIDE COMPOUNDS AS CCK2 MODULATORS
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
WO2004087700A8 (fr) Derives du benzenesulfonamide, leur procede de preparation et leur utilisation de la douleur
MY139368A (en) Novel cyclohexyl sulphones
WO2005003103A3 (en) 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases
WO2008023003A8 (de) Arzneimittelkombinationen zur behandlung von atemwegserkrankungen
UA86399C2 (ru) Применение 2,5 дигидроксибензолсульфоновой кислоты для изготовления лекарства, которые применяют для лечения болезней, зависимых от ангиогенеза
AU2003289652A1 (en) The use of compound helicid for manufacturing medicine to treat depresion and/or disorders caused by depresion
WO2003024996A3 (de) Antibakterielle makrozyklen
WO2005110413A3 (en) Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions
AU2003222667A1 (en) 1,3-thiazoles as lxr modulators in the treatment of cardiovascular diseases
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
WO2003094851A3 (en) 1,1- and 1,2-bisphosphonates as apoliprotein e modulators
WO2002070537A3 (en) Fusidic acid derivatives
WO2003029221A8 (de) Tetrahydroisochinoline, ihre herstellung und verwendung als schmerzmittel
WO2003000269A3 (de) Neue verwendung für pde 10a-inhibitoren
AU2003255429A1 (en) Use of treosulfan and derivatives thereof for treating multiple sclerosis
WO2002072527A3 (de) 1-butansäurederivate wie z.b. carbomethoxypropionylcyanid oder leflunomidderivate und deren therapeutische anwendung

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002772368

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002772368

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP